A Phase 1b combination trial of ARV-110 with standards-of-care in prostate cancer
Latest Information Update: 21 Dec 2020
Price :
$35 *
At a glance
- Drugs Bavdegalutamide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Arvinas
- 21 Dec 2020 New trial record
- 14 Dec 2020 According to an Arvinas media release, this study is expected to begin in 2021.